[{'publishedAt': '2024-08-19T18:00:00Z',
  'author': 'Genmab A/S',
  'urlToImage': 'https://ml-eu.globenewswire.com/Resource/Download/368a5dab-dfc5-4e1d-bfa6-2af5e5216fce',
  'description': 'Company Announcement   TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both......',
  'source': {'name': 'GlobeNewswire', 'id': None},
  'title': 'TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma',
  'url': 'https://www.globenewswire.com/news-release/2024/08/19/2932382/0/en/TEPKINLY-epcoritamab-Receives-Second-European-Commission-Approval-for-the-Treatment-of-Adults-with-Relapsed-Refractory-Follicular-Lymphoma.html',
  'content': 'Company Announcement\r\n<ul><li>TEPKINLYis the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymp… [+19901 chars]'},
 {'publishedAt': '2024-09-05T10:00:00Z',
  'author': 'Opthea Limited',
  'urlToImage': 'https://ml.globenewswire.com/Resource/Download/6b4960e3-b3f5-41cb-8993-66ea0b111361',
  'description': 'Daniel Geffken appointed Chief Financial Officer ad interim      Mike Campbell appointed Chief Commercial Officer      Three senior leaders appointed...',
  'source': {'name': 'GlobeNewswire', 'id': None},
  'title': 'Opthea Announces Executive Leadership Changes and Senior Hires',
  'url': 'https://www.globenewswire.com/news-release/2024/09/05/2941142/0/en/Opthea-Announces-Executive-Leadership-Changes-and-Senior-Hires.html',
  'content': 'Daniel Geffken appointed Chief Financial Officer ad interim\r\nMike Campbell appointed Chief Commercial Officer\r\nThree senior leaders appointed for Biometrics, Clinical Operations and Market Access\r\nME… [+12932 chars]'},
 {'publishedAt': '2024-08-15T20:15:00Z',
  'author': 'Alvotech',
  'urlToImage': 'https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44',
  'description': 'Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2024 and provided a summ…',
  'source': {'name': 'GlobeNewswire', 'id': None},
  'title': 'Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024',
  'url': 'https://www.globenewswire.com/news-release/2024/08/15/2931252/0/en/Alvotech-Reports-Record-Revenues-and-Adjusted-EBITDA-for-the-Second-Quarter-and-First-Six-Months-of-2024.html',
  'content': '<ul><li>Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023</li><li>Product revenues for the first six months were $66 mi… [+33143 chars]'},
 {'publishedAt': '2024-08-15T20:15:00Z',
  'author': 'Alvotech',
  'urlToImage': 'https://ml-eu.globenewswire.com/Resource/Download/17a8091d-68a6-47c1-968e-fcced99f1d44',
  'description': 'REYKJAVIK, Iceland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial result…',
  'source': {'name': 'GlobeNewswire', 'id': None},
  'title': 'Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024',
  'url': 'https://www.globenewswire.com/news-release/2024/08/15/2931251/0/en/Alvotech-Reports-Record-Revenues-and-Adjusted-EBITDA-for-the-Second-Quarter-and-First-Six-Months-of-2024.html',
  'content': '<ul><li>Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023</li></ul><ul><li>Product revenues for the first six months we… [+33229 chars]'}]